Backgrounds/Aims: Nucleos(t)ide analogues (NUCs) effectively suppress hepatitis B virus (HBV) replication, but hepatocellular carcinoma (HCC) recurrence often leads to HBV replication despite NUC therapy. The aim of this study was to determine whether high-dose tenofovir (TNF) therapy can suppresses HCC recurrence-associated HBV replication. Methods: We performed a single-arm prospective study to assess the clinical feasibility of high-dose TNF (hdTNF). We recruited 10 patients during September 2015 and followed up for 3 months or early drop-out. Results: All 10 patients had HCC of advanced stages due to HCC recurrence and gradual progression. The average age of patients was 51.2±4.7 years and 9 were male. Three patients did not tolerate the increased TNF dosage and were dropped out early. The other 7 patients were relatively tolerable to the increased dosage of TNF 5 tablets per day. One patient had mild gastrointestinal symptoms and another patient complained of insomnia. Increased HBV replication and HCC progression was observed despite hdTNF for 4-8 weeks. All 7 patients showed tumor progression during the 3 month follow-up. In these patients, blood HBV DNA before hdTNF was 50-200 copies/ml; and 4-8 weeks after hdTNF, the HBV replication status was not improved with blood HBV DNA of 50-300 copies/ml. This clinical study was terminated early after these negative results were confirmed. Conclusions: The results of this study indicated that high dose of TNF up to 5-fold the recommended dosage is not tolerated by a considerable proportion of patients and also ineffective in suppressing HCC progression-associated HBV replication. 
INTRODUCTION
It is well recognized that hepatitis B virus (HBV) infection and hepatocellular carcinoma (HCC) development are closely associated. Inhibition of HBV replication through nucleos(t)ides (NUCs) administration effectively prevents de novo HCC development and HCC recurrence in addition to blockage of fibrosis progression. [1] [2] [3] [4] [5] NUC with a high genetic barrier to resistance such as entecavir and tenofovir (TNF) can effectively suppress replication of HBV for a long time, but it is generally regarded that these agents do not control the covalently closed circular DNA (cccDNA) or integrated HBV DNA in the hepatocytes. 6 Active replication of HBV in HCC cells acting as a viral reservoir is well recognized as the clinical sequence of HCC recurrence following resection or liver transplantation. 7 It is generally accepted that HCC recurrence is a risk factor for posttransplant HBV recurrence. [7] [8] [9] Similarly, the blood HBV DNA can be converted to detectable status after HCC recurrence following NUC maintenance, despite negative status for a long time after HCC treatment.
The aim of the study was to determine whether high-dose TNF therapy (hdTNF) could suppress HCC recurrenceassociated HBV replication. We accordingly performed a clinical study and presented the preliminary result.
MATERIALS AND METHODS
This study was a single-arm prospective study to assess the clinical applicability of hdTNF. The primary purpose of this study was to assess whether hdTNF is tolerable to the adult patients and can suppress HCC recurrence-associated HBV replication. The secondary purpose was to determine whether it could have any oncological influence on HCC.
The patient selection criteria was as follows: HBV patients who were administered entecavir or TNF for more This clinical study was terminated early after confirming these negative results.
DISCUSSION
The preliminary results of this study indicated that hdTNF is not well tolerated by half of the adult patients, as well as ineffective in suppressing viral replication during HCC progression. Antitumor effect was also not expected in patients who were administered hdTNF over 1-2 months. The study was terminated early because we con- for HBV recurrence or replication following liver transplantation or resection. [7] [8] [9] In conclusion, the result of our study indicated that hdTNF using up to 5-folds of the recommended dosage is not only intolerable to a considerable proportion of patients but also ineffective to suppress HCC progressionassociated HBV replication.
